Cizzle Biotechnology strengthens North American rollout of CIZ1B lung cancer test (LON:CIZ)

Cizzle Biotechnology strengthens North American rollout of CIZ1B lung cancer test (LON:CIZ)Cizzle Biotechnology Holdings Plc (LON:CIZ) Executive Chairman Dr Allan Syms caught up with DirectorsTalk to discuss interim results and progress in commercialising its CIZ1B lung cancer test. So, the company was really created and formed to solve that problem, which was: let’s find a means to detect lung cancer early. A lot of work’s gone into the validation process and we think that’s going extremely well. If 14.5 million Americans need to be screened for lung cancer, you need a test that is easy to do, simple to do, can be done and catch lung cancer at its earliest stage, but can be done right the way across North America. What’s really needed is a better way to identify whether or not any of those suspicious lung nodules really are a lung cancer.